Trial · NCT02108652
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Percentage of Participants With a Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) as Assessed by the Independent Review Facility (IRF) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Cohort 2: Participants With Second-line or Beyond Treatments | 15.8 | 95% Confidence Interval 11.9 to 20.4 | percentage of participants | |
| Percentage of Participants With a Confirmed Objective Response of CR or PR as Assessed by the Investigator According Modified RECIST | Cohort 2: Participants With Second-line or Beyond Treatments | 19.7 | 95% Confidence Interval 15.4 to 24.6 | percentage of participants | |
| Duration of Response (DOR) as Assessed by the IRF According to RECIST v1.1 | Cohort 2: Participants With Second-line or Beyond Treatments | NA | Full Range 2.1 to NA | months | |
| DOR as Assessed by the Investigator According to RECIST v1.1 | Cohort 2: Participants With Second-line or Beyond Treatments | 20.50 | Full Range 2.1 to 20.5 | months | |
| DOR as Assessed by the Investigator According to Modified RECIST | Cohort 2: Participants With Second-line or Beyond Treatments | 20.50 | Full Range 2.1 to 20.5 | months | |
| Percentage of Participants With Death or Disease Progression as Assessed by the IRF According to RECIST v1.1 | Cohort 2: Participants With Second-line or Beyond Treatments | 88.4 | percentage of participants | ||
| Progression-Free Survival (PFS) as Assessed by the IRF According to RECIST v1.1 | Cohort 2: Participants With Second-line or Beyond Treatments | 2.10 | 95% Confidence Interval 2.07 to 2.14 | months | |
| Percentage of Participants With Death or Disease Progression as Assessed by the Investigator According to RECIST v1.1 | Cohort 2: Participants With Second-line or Beyond Treatments | 89.7 | percentage of participants | ||
| PFS as Assessed by the Investigator According to RECIST v1.1 | Cohort 2: Participants With Second-line or Beyond Treatments | 2.10 | 95% Confidence Interval 2.07 to 2.14 | months | |
| Percentage of Participants With Death or Disease Progression as Assessed by the Investigator According to Modified RECIST | Cohort 2: Participants With Second-line or Beyond Treatments | 87.1 | percentage of participants | ||
| PFS as Assessed by the Investigator According to Modified RECIST | Cohort 2: Participants With Second-line or Beyond Treatments | 2.56 | 95% Confidence Interval 2.14 to 3.61 | months | |
| Percentage of Participants With a Confirmed Objective Response of CR or PR as Assessed by the Investigator According RECIST v1.1 | Cohort 2: Participants With Second-line or Beyond Treatments | 16.5 | 95% Confidence Interval 12.5 to 21.1 | percentage of participants | |
| Percentage of Participants Who Died | Cohort 2: Participants With Second-line or Beyond Treatments | 72.9 | percentage of participants | ||
| Overall Survival (OS) | Cohort 2: Participants With Second-line or Beyond Treatments | 7.9 | 95% Confidence Interval 6.7 to 9.3 | months | |
| Percentage of Participants Alive at 1-year | Cohort 2: Participants With Second-line or Beyond Treatments | 36.9 | 95% Confidence Interval 31.4 to 42.3 | percentage of participants | |
| Maximum Serum Concentration (Cmax) of Atezolizumab | Cohort 2: Participants With Second-line or Beyond Treatments | 364 | Standard Deviation 120 | microgram(s)/milliliter (mcg/mL) | |
| Minimum Serum Concentration (Cmin) of Atezolizumab | Cohort 2: Participants With Second-line or Beyond Treatments | Pre-dose Cycle 1 (n=303) | 0.0252 | Standard Deviation 0.429 | mcg/mL |
| Minimum Serum Concentration (Cmin) of Atezolizumab | Cohort 2: Participants With Second-line or Beyond Treatments | Pre-dose Cycle 2 (n=269) | 74.2 | Standard Deviation 29.9 | mcg/mL |
| Minimum Serum Concentration (Cmin) of Atezolizumab | Cohort 2: Participants With Second-line or Beyond Treatments | Pre-dose Cycle 3 (n=146) | 120.0 | Standard Deviation 59.5 | mcg/mL |
| Minimum Serum Concentration (Cmin) of Atezolizumab | Cohort 2: Participants With Second-line or Beyond Treatments | Pre-dose Cycle 4 (n=186) | 147.0 | Standard Deviation 77.7 | mcg/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02108652/results